MMP2 and prostate cancer: In in vitro tests using prostate cancer cell lines, the BTK inhibitor ibrutinib was found to drastically reduce prostate cancer cell proliferation, wound healing, migration, and invasion, as well as block tumor cell matrix metalloproteinase-2 (MMP-2) and MMP-9 protein production [55].